Hinge Health (HNGE) CEO converts Class B and sells 166,665 shares

Rhea-AI Filing Summary

Hinge Health, Inc. CEO, Co-Founder, director and 10% owner Daniel Antonio Perez reported a planned share sale. On February 12, 2026, he converted 166,665 shares of Class B Common Stock into the same number of Class A shares at $0 per share, then sold 166,665 Class A shares in open-market transactions at a weighted average price of $40.2635, under a Rule 10b5-1 trading plan adopted on September 11, 2025. Following these transactions, his directly held Class A position reported in this filing is 0 shares, while he directly holds 9,488,845 Class B shares and has additional indirect holdings through his spouse.

Insider Trade Summary

Net Seller: 166,665 shares ($6,710,516)

Net Sell 5 txns

Insider Perez Daniel Antonio

Role CEO & Co-Founder

Sold 166,665 shs ($6.71M)

Type	Security	Shares	Price	Value
Conversion	Class B Common Stock	166,665	$0.00	--
Conversion	Class A Common Stock	166,665	$0.00	--
Sale	Class A Common Stock	166,665	$40.2635	$6.71M
holding	Class B Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class B Common Stock — 9,488,845 shares (Direct); Class A Common Stock — 166,665 shares (Direct); Class B Common Stock — 515,705 shares (Indirect, By Spouse); Class A Common Stock — 35,470 shares (Indirect, By Spouse)

Footnotes (1)

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2025. Represents the weighted average sale price. The lowest price at which shares were sold was $40.00 and the highest price at which shares were sold was $40.88. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation. Excludes 4,721,252 performance stock units held by the Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perez Daniel Antonio

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CA 94015

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Co-Founder

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/12/2026		C		166,665	A	$0	166,665	D
Class A Common Stock	02/12/2026		S(1)		166,665	D	$40.2635(2)	0	D
Class A Common Stock								35,470	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B Common Stock	(3)	02/12/2026		C			166,665	(3)	(3)	Class A Common Stock	166,665	$0	9,488,845(4)	D
Class B Common Stock	(3)							(3)	(3)	Class A Common Stock	515,705		515,705	I	By Spouse

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $40.00 and the highest price at which shares were sold was $40.88. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.

4. Excludes 4,721,252 performance stock units held by the Reporting Person.

	/s/ James Budge, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did HNGE CEO Daniel Antonio Perez report?

Daniel Antonio Perez reported converting and selling shares. He converted 166,665 Class B shares into 166,665 Class A shares, then sold all 166,665 Class A shares in open-market trades, as disclosed in this Form 4 insider transaction report.

How many Hinge Health (HNGE) shares did the CEO sell and at what price?

The CEO sold 166,665 Class A shares. These were sold at a weighted average price of $40.2635 per share, with individual sale prices ranging from $40.00 to $40.88, according to the detailed pricing footnote in the filing.

Was the HNGE CEO’s share sale under a Rule 10b5-1 trading plan?

Yes, the sale was under a Rule 10b5-1 plan. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan that Daniel Antonio Perez adopted on September 11, 2025, indicating the trades were pre-arranged.

What Hinge Health (HNGE) shares does the CEO hold after this Form 4 transaction?

After the reported transactions, direct Class A holdings are zero. The filing shows 0 directly held Class A shares, 9,488,845 directly held Class B shares, and additional indirect holdings of Class A and Class B shares through his spouse.

What is the relationship of Daniel Antonio Perez to Hinge Health (HNGE)?

Daniel Antonio Perez is a key insider at Hinge Health. He is identified as CEO, Co-Founder, a director, and a 10% owner of the company, making his transactions material for monitoring insider ownership levels.

How are Hinge Health (HNGE) Class B shares treated in this Form 4?

Class B shares are convertible into Class A shares. The filing explains each Class B share can be converted into one Class A share at the holder’s election or automatically upon certain transfers or events described in the company’s charter.